November 21, 2012
NTNU Professor Marit Otterlei, APIM Therapeutics's Chief Scientific Officer and primary inventor gives an interview to Norwegian daily journal Sunnmørsposten about APIM's anti-cancer development program. A copy of the article (in Norwegian) is available at this address.

November 14, 2012
Professor M. Otterlei, APIM Therapeutics's Chief Scientific Officer and primary inventor, and her collaborators at the Norwegian University of Science and Technology (NTNU) publish a scientific paper at PLOS One showing functional implication of XPA and PCNA in Nucleotide Excision Repair (NER) mechanisms associated with the replisome. The publication provides validation of the APIM motif, a newly identified AlkB homolog 2 PCNA interacting motif mediating interactions of a large number of proteins involved in DNA repair, cell cycle control and apoptosis with PCNA upon stress. A full copy of the article can be downloaded here.

November 9, 2012
Daily Norwegian journal Adressa interviews NTNU Professor and Chief Scientific Officer of APIM Therapeutics, M. Otterlei, about the promising anti-cancer properties of APIM's drug candidates. A copy of the article (in Norwegian) is available at this address.

October 17, 2012
APIM Therapeutics announced today conclusion of a financing round led by Norsk Innovasjonskapital III AS, a leading Norwegian VC firm in syndication with existing APIM investors, Sarsia Seed, Birk Venture and Ro Invest. Financing will be used to further advance the preclinical development of APIM Therapeutics' anti-cancer lead compound ATX-101. For more information, please visit the following web site link:

August 16, 2012
APIM Therapeutics has been selected to present at the 12th Biotech In Europe Investor Forum. The conference, which takes place in October 1-2, 2012 in Zurich, brings together venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders.

April 23, 2012
Biocentury, a leading biotechnology publication, features APIM Therapeutics in an article published on-line on April 23rd. The article discusses in detail the novel therapeutic approach of the company and its implications for the development of novel cancer therapies. A full copy of the article can be downloaded here.

March 15, 2012
APIM Therapeutics will present a poster entitled "A novel APIM-motif comprising peptide drug potentiates the action of several chemotherapeutic drugs by blocking the interaction between PCNA and key proteins involved in DNA repair, apoptosis and cell cycle control" at the Annual Meeting of the American Cancer Association (AACR), taking place in Chicago, USA (March 31- April 4). The poster (#4676) will be presented on Tuesday, April 03, at the poster session 30, Hall F, 1:00 pm - 5:00 pm.

February 6, 2012
APIM Therapeutics has been selected to present at the 5th Annual European Life Science CEO Forum For Partnering & Investing. The conference, which takes place in March 6-7, 2012 in Zurich, will focus on executive-level networking, deal-making and partnering in the Life Science and Biotech Industries.

February 1, 2012
APIM Therapeutics joins the Oslo Cancer Cluster, an oncology research cluster comprising academic institutions, biotech and pharma companies, support groups, financial institutions and regional development players in the field of cancer R & D.

January 5, 2012
A panel of industry experts has selected APIM Therapeutics to present at BIO-Europe Spring 2012, the springtime counterpart to BIO-Europe. The conference, which takes place in March 19–21, 2012 in Amsterdam, focuses on biotechnology companies interested in partnering their technologies or products, initiating strategic alliances, or tapping into the international financing network.

Visit Media Center 2017
Visit Media Center 2015 & 2016
Visit Media Center 2013 & 2014
Visit Media Center 2010 & 2011

To learn more the APIM-motif, ATX-101 and PCNA, please see attached the publications (given as pdf files):

1. Gilljam KM et al, 2009. Identification of a novel, widespread, and functionally important PCNA-binding motif. J Cell Biol 186, pp645-654.

2. Müller R et al, 2013. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7).

3. Baglo Y et al, 2014. Enhanced efficacy of bleomycin in bladder cancer cells by photochemical internalization. Biomed Res Int. 2014;2014:921296.

4. Gederaas OA et al, 2014. Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Transl Oncol. 2014 Dec;7(6):812-23.

5. Olaisen C et al, 2014. PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling. Cell Signal. 2015 Jul;27(7):1478-87.

The following posters presented in TAT and AACR 2016 meetings provide latest efficacy data in bladder and breast cancer models as well as genomic and kinomic analysis conducted in these tumors:

6. Poster presented in the 14th International Congress on Targeted Anticancer Therapies.

7. Poster presented in the AACR Precision Medicine Series Conference: Targeting the Vulnerabilities of Cancer. 

For an excellent review discussing the druggability of PCNA and ATX-101:

8. Wang Shao-Chun, 2014. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014 Apr;35(4):178-186.



APIM Therapeutics AS is a spin-off from the Norwegian University of Science and Technology (NTNU).

Visit our About Us page to find out more.

About NTNU
The Norwegian University of Science and Technology (NTNU) is one of the most prominent Academic centers in Norway. It is home to a growing number of spin-out companies including APIM Therapeutics AS. To learn more about NTNU, please see

About Sarsia Seed
Sarsia Seed is a Norwegian seed stage life science fund that has invested in APIM Therapeutics. Visit to find out more.

About Birk Venture
Birk Venture is a Scandinavian venture company exclusively focusing on innovative life science companies. Visit to find out more.

About Norsk Innovasjonskapital
Norsk Innovasjonskapital is a leading Norwegian venture capital company focusing on selective investments in various industry fields including life sciences. Visit to find out more.